Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 380

1.

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL.

J Natl Cancer Inst. 2004 Nov 3;96(21):1603-10.

PMID:
15523089
2.

Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.

Brunstein F, Hoving S, aan de Wiel-Ambagtsheer G, de Bruijn EA, Guetens G, Eggermont AM, ten Hagen TL.

Cancer Immunol Immunother. 2007 Apr;56(4):573-80. Epub 2006 Aug 1.

PMID:
16896966
3.

Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.

Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL.

Cancer Res. 2005 May 15;65(10):4300-8.

4.

Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, de Waal RM, Ruiter DJ.

Br J Cancer. 1996 Dec;74(12):1908-15.

5.

A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.

Bauer TW, Gutierrez M, Dudrick DJ, Li J, Blair IA, Menon C, Fraker DL.

Surgery. 2003 Apr;133(4):420-8.

PMID:
12717360
6.

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.

Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, de Bruijn EA, Eggermont AM, ten Hagen TL.

Anticancer Drugs. 2006 Sep;17(8):949-59.

PMID:
16940805
7.

Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.

van Ijken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont AM.

J Immunother. 2000 Jul-Aug;23(4):449-55.

PMID:
10916754
8.

Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.

de Wilt JH, Soma G, ten Hagen TL, Kanou J, Takagi K, Nooijen PT, Seynhaevel AL, Eggermont AM.

Anticancer Res. 2000 Sep- Oct;20(5B):3491-6.

PMID:
11131652
9.

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.

de Wilt JH, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve AL, ten Hagen TL, Eggermont AM.

Br J Cancer. 2000 Nov;83(9):1176-82.

10.
11.

Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.

Brunstein F, Eggermont AM, de Wiel-Ambagtsheer Ga, van Tiel ST, Rens J, ten Hagen TL.

Ann Surg Oncol. 2007 Feb;14(2):795-801. Epub 2006 Nov 10.

PMID:
17096052
12.

Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.

Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM.

Br J Surg. 1996 Apr;83(4):551-5.

PMID:
8665257
13.
14.

High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.

Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM.

Cancer. 1997 Mar 15;79(6):1129-37.

PMID:
9070490
15.

Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats.

Manusama ER, Nooijen PT, Stavast J, de Wilt JH, Marquet RL, Eggermont AM.

J Surg Res. 1998 Aug;78(2):169-75.

PMID:
9733636
16.

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, Kroon BB.

Eur J Surg Oncol. 2001 Jun;27(4):390-5.

PMID:
11417986
17.
18.

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.

van der Veen AH, Seynhaeve AL, Breurs J, Nooijen PT, Marquet RL, Eggermont AM.

Br J Cancer. 1999 Feb;79(3-4):433-9.

19.

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL.

Br J Cancer. 2000 Feb;82(4):973-80.

20.

Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.

Gutman M, Sofer D, Lev-Chelouche D, Merimsky O, Klausner JM.

Invasion Metastasis. 1997;17(4):169-75.

PMID:
9778589

Supplemental Content

Support Center